Tumor Mutational Burden as a Pan-cancer Biomarker for Immunotherapy: The Limits and Potential for Convergence

Antonio Passaro, Albrecht Stenzinger, Solange Peters

Research output: Contribution to journalArticlepeer-review

Abstract

A recent study in The Lancet Oncology reports that high tumor mutational burden (TMB) is associated with response to anti-PD-1 pembrolizumab, leading to the second FDA approval of a tissue-agnostic predictive biomarker for immunotherapy in solid tumors. This is a step forward in realizing the full potential of cancer immunotherapy.

Original languageEnglish
Pages (from-to)624-625
Number of pages2
JournalCancer Cell
Volume38
Issue number5
DOIs
Publication statusPublished - Nov 9 2020

ASJC Scopus subject areas

  • Oncology
  • Cell Biology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Tumor Mutational Burden as a Pan-cancer Biomarker for Immunotherapy: The Limits and Potential for Convergence'. Together they form a unique fingerprint.

Cite this